Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering

Astria Therapeutics Announces Pricing of $64

Million Underwritten Offering

BOSTON, Mass., October 11, 2023 -

Astria Therapeutics, Inc. ("Astria Therapeutics," "Astria," the "Company," "our,"

or "us") (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological

diseases, today announced the pricing of an underwritten offering of (i) 8,253,895 shares of its common stock and accompanying common

stock warrants to purchase an aggregate of 6,190,418 shares of common stock, and (ii) to certain investors in lieu of common stock

who so choose, pre-funded warrants to purchase up to an aggregate of 1,571,093 shares of common stock and accompanying common stock warrants

to purchase up to an aggregate of 1,178,320 shares of common stock. Each share of common stock and accompanying common stock warrant

are being sold together at a combined public offering price of $6.514, and each pre-funded warrant and accompanying common stock warrant

are being sold together at a combined public offering price of $6.513. The aggregate gross proceeds of the offering are expected to be

approximately $64 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each pre-funded

warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded

warrants are exercised in full. Each common stock warrant will have an exercise price of $8.025 per share, will be exercisable immediately

and will expire 5 years from the date of issuance.

All of the securities

are being offered by Astria. The offering is expected to close on or about October 16, 2023, subject to satisfaction of customary

Jefferies and Evercore

ISI are acting as joint book-running managers for the offering. LifeSci Capital and Oppenheimer & Co. are acting as co-lead managers.

The securities described

above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-271848), which was declared effective

by the Securities and Exchange Commission (the "SEC") on May 23, 2023. The offering is being made only by means of a

prospectus supplement and the accompanying prospectus. A final prospectus supplement relating to the offering will be filed with the

SEC and will be available at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus

may be obtained for free by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York,

NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention:

Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200,

or by email at ecm.prospectus@evercore.com.

does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be

any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration

or qualification under the securities laws of any such jurisdiction.

About Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company,

and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead

program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema.

STAR-0310 is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis.

Cautionary Note Regarding Forward Looking Statements

Any statements in this press release about future

expectations, plans and prospects for the Company, including statements about the anticipated completion of the offering and the expected

gross proceeds of the offering, among other things, statements containing the words "believes," "anticipates,"

"plans," "expects," "may" and similar expressions, constitute forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking

statements as a result of various important factors, including: risks and uncertainties associated with market conditions, the satisfaction

of customary closing conditions relating to the offering, as well as uncertainties inherent in the initiation and completion of preclinical

studies and clinical trials and clinical development of the Company's product candidates; whether interim results from a clinical

trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct

trials or to market products; availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses

and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company's

product candidates; and general economic and market conditions and other factors discussed in the "Risk Factors" section of

the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which is on file with the SEC, and

in other filings that the Company may make with the SEC in the future. In addition, the forward-looking statements included in this press

release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments

will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some

point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied

upon as representing the Company's views as of any date subsequent to the date of this release.

Investor Relations and Media: